Key Highlights
● Neumora Therapeutics confirmed in a June 2026 release that navacaprant is discontinued, its once-flagship depression drug.
● The company spent the past 18 months absorbing back-to-back Phase 3 failures of the drug.
● A new CEO now leads the company's turnaround effort, following the loss of the lead program.
● Neumora is refocusing on a slimmer pipeline as it works to rebuild its clinical narrative.
Neumora Therapeutics (NASDAQ: NMRA) is a clinical-stage neuroscience biotech that spent the past 18 months absorbing back-to-back Phase 3 failures of its once-flagship depression drug, navacaprant. The company confirmed in a June 2026 release that navacaprant is discontinued after its KOASTAL-2 and KOASTAL-3 trials both missed their primary endpoints, following an earlier KOASTAL-1 miss in January 2025. On August 14, 2026, Neumora reported second-quarter results alongside a Leadership change: longtime executive Joshua Pinto, Ph.D. was named president and CEO, succeeding co-founder Paul Berns, who moves to Executive Chair. Shares fell roughly 7.5% on the news despite a narrower net loss, underscoring investor skepticism about the post-navacaprant pipeline.
Latest Development
Neumora's August 14, 2026 press release delivered two headline items. First, the company formalized its leadership transition: Pinto, who joined Neumora in 2021 and had served as president since February 2025, was elevated to president and CEO effective immediately. Berns, who had been serving as CEO since February 2025, shifted to Executive Chair, while Doron Sagman, M.D. was named chief medical officer. Second, Neumora reported Q2 2026 financials showing a net loss of $43.1 million ($0.23 per share), down from $52.7 million ($0.33 per share) in the same period a year earlier, with cash and equivalents of $116.8 million as of June 30, 2026.
The financial update reaffirmed guidance from the company's June 2026 pipeline reset: cash is expected to fund operations into the third quarter of 2027. That runway reflects a roughly 35% workforce reduction announced alongside the navacaprant discontinuation, targeted at approximately $10 million in annualized savings against about $2 million in one-time restructuring costs.
What the Numbers Show
Neumora's KOASTAL Phase 3 program for navacaprant, a kappa opioid receptor (KOR) antagonist, has a well-documented failure history. KOASTAL-1 missed its primary endpoint in January 2025, failing to show a statistically significant improvement in depression symptoms versus placebo at six weeks. In response, Neumora modified the two remaining pivotal trials, reducing site count, partnering with the Massachusetts General Hospital Trials Network for enhanced medical monitoring, and screening for patients enrolled simultaneously in multiple studies, while also scrapping a separate Phase 2 bipolar-depression trial to conserve resources.
Those modifications did not salvage the program. According to Neumora's June 2026 release, KOASTAL-2 (430 patients) showed navacaprant 80 mg improving MADRS depression scores by -12.2 points versus -12.0 for placebo at week 6 (p=0.813), statistically indistinguishable from placebo. KOASTAL-3 (422 patients) fared no better, with navacaprant actually trailing placebo numerically (-10.1 vs. -10.8, p=0.480). A pre-specified analysis of 426 patients enrolled after the study-optimization changes also showed no separation (-12.1 vs. -12.1, p=0.976). Safety was reported as consistent with prior studies. Following these results, Neumora said it is "discontinuing development of navacaprant as it continues to focus on advancing the rest of its best-in-class clinical portfolio."
On the balance sheet, R&D expense fell to $29.3 million in Q2 2026 from $38.7 million a year earlier, and G&A expense dropped to $12.9 million from $15.3 million, reflecting the cost cuts tied to the navacaprant wind-down and layoffs.
Why Investors Are Paying Attention
With its lead program terminated, Neumora is effectively a pipeline-reset story. Investor attention has shifted to three earlier-stage assets: NMRA-511, a V1a receptor antagonist for agitation in Alzheimer's disease, with multiple ascending-dose expansion cohort data expected in Q4 2026 and a Phase 2 study planned to begin by year-end; NMRA-898, an M4 positive allosteric modulator for schizophrenia, with Phase 1 multiple-ascending-dose data expected in the second half of 2026; and NMRA-215, an NLRP3 inhibitor being developed for obesity and cardiometabolic disease, which reported favorable preclinical weight-loss data and is on track for an IND submission and Phase 1 initiation by the end of 2026. The obesity angle in particular has generated interest given the broader market enthusiasm for metabolic-disease therapeutics, though NMRA-215 remains preclinical.
Bull Case
Bulls argue Neumora enters this reset with real balance-sheet discipline: a leaner cost structure, a CFO-confirmed runway into Q3 2027, and three distinct near-term catalysts (NMRA-511, NMRA-898, NMRA-215) spread across neuropsychiatry and metabolic disease rather than a single binary bet. New CEO Joshua Pinto has institutional continuity, having been at Neumora since 2021, and the appointment of a dedicated chief medical officer signals a sharpened focus on clinical execution after two costly trial misses. If any of the H2 2026/Q4 2026 data readouts, particularly the NMRA-511 Alzheimer's-agitation cohort or NMRA-898 schizophrenia data, show a clean signal, the current sub-$320 million market cap could look inexpensive relative to the size of those indications.
Bear Case
The bear case starts with the plain fact that Neumora's most advanced, most-derisked asset is now dead after three consecutive Phase 3/pivotal misses. Every remaining program is early-stage (preclinical-to-Phase 1), meaning years of expensive, high-risk clinical development remain before any potential approval, and repeated failure risk is inherent to CNS drug development. Cash of $116.8 million, while providing runway into Q3 2027, will likely require additional financing before any of the current pipeline reaches a pivotal trial, a dilution risk for existing shareholders, particularly with shares trading near $1.73. The 7.5% single-day stock decline on the Q2 print, despite improved loss metrics, suggests the market is pricing in skepticism about pipeline replacement value and possibly further leadership or strategic uncertainty.
What Could Move the Stock Next?
Nearer-term catalysts include NMRA-898 Phase 1 MAD data expected in the second half of 2026, and by Q4 2026: NMRA-511 dose-expansion cohort data, the NMRA-215 IND submission, and progress toward initiating Phase 1/Phase 2 studies for both programs. Any additional executive changes under the new CEO, updates on cash use or potential financing, and broader biotech sector sentiment around CNS and obesity-focused clinical-stage names could also move shares.
A Reset Built Around New Leadership
Neumora Therapeutics has moved from a single-asset depression story to a multi-program reset following navacaprant's discontinuation after three failed Phase 3/pivotal readouts in KOASTAL-1, -2, and -3. New CEO Joshua Pinto inherits a leaner, restructured company with cash into Q3 2027 and three earlier-stage programs, NMRA-511, NMRA-898, and NMRA-215, as the next tests of the platform's viability. The August 14, 2026 stock decline despite improved quarterly financials illustrates that investors are focused less on cost control and more on whether any of the remaining pipeline can generate a positive clinical signal. Data expected later in 2026 across Alzheimer's agitation, schizophrenia, and obesity programs will be the next meaningful checkpoints for a company still working to rebuild credibility after its lead program's collapse.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...